Assessing the Candidacy of MARCH1 as a Therapeutic Target for Treatment of Asthma
Abstract
This application addresses the Topic Area “Respiratory Health” with a specific focus on “asthma.” Asthma is a serious economic and health concern in the United States. Although multiple controlling medications exist, many of them exert significant side effects while treatment is not sufficiently achieved. Therefore, development of better drugs by identifying new molecular targets is in urgent need. We have recently found that mice deficient in a protein named MARCH1 were resistant to developing asthmatic airway inflammation to house dust mite allergens, one of the major causes of asthma. This novel finding strongly suggests that MARCH1 plays an essential role in the development and possibly exacerbation of asthma. In this application, we aim to assess the candidacy of MARCH1 as a therapeutic target for treatment of asthma. If successful, the study outcome will serve as a basis for development of novel drugs that will substantially improve health of patients with asthma.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Oct 29, 2018
- Source ID
- W81XWH1810110
Entities
People
- Jeoung-sook Shin
Organizations
- United States Army
- University of California, San Francisco